⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1299563 | 0.82 | — | — | |
| SCHEMBL11257556 | 0.76 | — | — | |
| SCHEMBL310610 | 0.72 | NISCH (0.39) | — | |
| SCHEMBL16338698 | 0.70 | — | — | |
| SCHEMBL14744755 | 0.70 | — | — | |
| SCHEMBL337651 | 0.70 | — | — | |
| SCHEMBL337685 | 0.67 | — | — | |
| SCHEMBL6322559 | 0.65 | — | — | |
| SCHEMBL20522165 | 0.63 | — | — | |
| SCHEMBL6319373 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023244815-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | claimed |
| WO-2023225244-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | BIOGEN MA INC. (US) | 2023-11-23 | — | — | WO | claimed |
| WO-2024137981-A1 | NAMPT MODULATORS | CYTOKINETICS, INCORPORATED (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024017977-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023244815-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023225244-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | BIOGEN MA INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230127046-A1 | G9a INHIBITOR | RIKEN (JP) | 2023-04-27 | — | — | US | disclosed |
| US-20230021177-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | NXERA PHARMA UK LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| WO-2022255399-A1 | G9A INHIBITOR | 国立研究開発法人理化学研究所 | 2022-12-08 | — | — | WO | disclosed |
| US-20220204495-A1 | INHIBITING TRABID | Valo Health, LLC | 2022-06-30 | — | — | US | disclosed |
| EP-4008720-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVE USED AS TLR8 AGONIST | BeiGene, Ltd. (KY) | 2022-06-08 | — | — | EP | disclosed |
| US-9249130-B2 | 1,2,4-triazine-4-amine derivatives | HEPTARES THERAPEUTICS LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| WO-2015019325-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-02-12 | — | — | WO | disclosed |
| US-20150005276-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | NXERA PHARMA UK LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
| US-8809525-B2 | 1,2,4-triazine-4-amine derivatives | HEPTARES THERAPEUTICS LIMITED (GB) | 2014-08-19 | — | — | US | disclosed |
| US-20130029963-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | HEPTARES THERAPEUTICS LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| EP-2531492-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | Heptares Therapeutics Limited (GB) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011095625-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | HEPTARES THERAPEUTICS LIMITED (GB) | 2011-08-11 | — | — | WO | disclosed |
| EP-1243268-A1 | MEDICINAL COMPOSITION | Nippon Shinyaku Co., Ltd. (JP) | 2002-09-25 | — | — | EP | disclosed |
| EP-1156045-A1 | AMIDE DERIVATIVES AND DRUG COMPOSITIONS | Nippon Shinyaku Co., Ltd. (JP) | 2001-11-21 | — | — | EP | disclosed |